Browse by category

Innovent Biologics’ supplementary application for the 9 mg dosage of mazdutide, an innovative glucagon (GCG)/ glucagon-like peptide-1 (GLP-1) dual receptor agonist, for the long-term weight management in adults with moderate to severe obesity has been accepted for review by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA). This application of mazdutide 9 mg aims to address a pressing unmet clinical need in China by offering a hig

Outcomes from the Phase 3 clinical trial of mazdutide, a first-in-class dual glucagon (GCG)/glucagon-like peptide-1 (GLP-1) receptor agonist, in Chinese adults with obesity (GLORY-2) has met the primary endpoints and all key secondary endpoints. Innovent Biologics plans to submit the new drug application (NDA) of mazdutide 9 mg for weight management to the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) in the near term. GLORY-2 is

Innovent Biologics’ New Drug Application (NDA) for mazdutide (Innovent R&D code: IBI362), a glucagon-like peptide-1 receptor (GLP-1R) and...

The 48-week outcomes from a Phase 2 clinical study of higher dose (9mg) mazdutide in Chinese subjects with obesity have demonstrated...

Innovent Biologics has announced that the results of a phase 1b study of mazdutide (IBI362), a glucagon-like peptide-1 (GLP-1) and...